vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv's clinical pipeline is led by cadisegliatin, a potential adjunctive ...

vTv Therapeutics (NASDAQ:VTVT) just reported results for the second quarter of 2024. vTv Therapeutics reported earnings per share of -81 cents. The company did not report any revenue for the quarter.

VOV.VN - Báo điện tử VOV, tin tức thời sự về chính trị, kinh tế, đời sống, xã hội, pháp luật, thể thao, văn hóa, giải trí, ...

HIGH POINT, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq ... reported financial results for the fourth quarter and year ended December 31, 2024, and provided an update on ...

In March 2025, vTv Therapeutics announced that the clinical hold placed by the FDA in July 2024 on the cadisegliatin clinical program was lifted on March 14, 2025, following the Company's ...